Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder.

摘要

Aripiprazole is a recently introduced antipsychotic medication that acts as a partial agonist at dopamine D2 and serotonin receptor 1A. It is also a serotonin receptor 2A antagonist. These dopamine-serotonin-stabilizing properties might be of therapeutic value in obsessive-compulsive disorder (OCD) as suggested by an open-label aripiprazole monother-apy study.' Meanwhile, antipsychotic augmentation strategy is relevant in OCD, as almost half of patients fail to respond to an initial adequate trial of selective serotonin reuptake inhibitors (SSRIs).2 Augmentation with aripiprazole has been reported to be effective in subjects with treatment-resistant OCD.